Pharmaceutical manufacturing units regularly need to upgrade their facilities, equipment and quality systems to meet changing regulatory and manufacturing standards. For eligible existing pharmaceutical units, the Revamped Pharmaceutical Technology Upgradation Assistance Scheme provides financial support for technology and quality-related improvements.

What Is the RPTUAS Scheme?

RPTUAS is a sub-scheme under the Government of India’s Strengthening of Pharmaceuticals Industry initiative. It was introduced to support existing pharmaceutical manufacturing units in upgrading their facilities toward compliance with Revised Schedule M and WHO-GMP standards.

Businesses researching the RPTUAS subsidy scheme should first understand that eligibility and financial assistance depend on factors such as the unit’s turnover, existing manufacturing status and proposed eligible investment.

How Much Financial Assistance Is Available?

Under the scheme, eligible pharmaceutical units can receive financial assistance ranging from 10% to 20% of eligible investment, subject to a maximum assistance of ₹2 crore per unit. The applicable percentage is based on the average turnover of the unit during the previous three years.

Units with average turnover between ₹1 crore and ₹50 crore may qualify for assistance at 20%, while units in the ₹50 crore to ₹250 crore range fall under the 15% slab. Units with turnover between ₹250 crore and ₹500 crore are covered under the 10% slab.

Why Technology Upgradation Matters

Pharmaceutical manufacturing involves strict requirements relating to production areas, utilities, testing systems, quality control and documentation. Technology upgrades can therefore include improvements in manufacturing equipment, clean-room facilities, utilities, laboratories and other eligible areas linked to regulatory compliance.

The broader objective of the pharmaceutical technology upgradation scheme is to help existing units improve manufacturing standards and strengthen their ability to comply with Revised Schedule M and WHO-GMP requirements.

Who Should Review Eligibility?

The scheme is intended for existing pharmaceutical manufacturing units rather than businesses that are only engaged in trading activities. Turnover limits, investment timing, regulatory status and the nature of proposed expenditure should be reviewed before proceeding with an application.

Businesses should also ensure that the proposed expenditure falls within eligible categories and that the same investment is not being claimed improperly under overlapping assistance mechanisms.

Why Documentation Is Important

Applications may involve documents relating to the manufacturing unit, financial records, proposed equipment or improvements and regulatory compliance.

Maintaining organised quotations, invoices, investment records and supporting certificates becomes particularly important because financial assistance is linked to eligible expenditure and achievement of specified compliance conditions.

Latest Change in Subsidy Release Conditions

In March 2026, the Department of Pharmaceuticals further modified the RPTUAS guidelines. For the first instalment, a shortlisted applicant can submit either a Revised Schedule M certificate or a WHO-GMP certificate along with CA-certified eligible expenditure incurred after 1 January 2024.

For the second instalment, the applicant is required to submit the remaining certificate along with the applicable certified expenditure documentation.

Importance of Planning Before Investment

Pharma units considering technology upgrades should review scheme conditions before finalising major expenditure. The nature of machinery, infrastructure improvement, documentation and timing of investment can affect whether an expenditure qualifies for assistance.

A preliminary review of eligibility and documentation can therefore help the unit understand the scheme requirements before committing significant resources.

Conclusion

RPTUAS provides a structured financial support mechanism for eligible existing pharmaceutical units undertaking technology and quality upgrades. The scheme links assistance to turnover, eligible investment and achievement of specified regulatory standards.

For pharmaceutical manufacturers planning modernization, understanding eligibility, expenditure conditions, documentation and certification requirements can help in preparing a more organised application and investment plan.